BioNTech's Cancer Candidate Nears Regulatory Filing Amid Financial Transition

BioNTech plans 2026 FDA filing for endometrial cancer drug BNT323/DB-1303, showing 47.9% response in Phase 2. This marks a key pivot from COVID vaccine revenue as the company posts a €1.14B loss.

BioNTech is preparing to submit its first oncology drug for U.S. approval later this year, a pivotal step in its strategic shift away from pandemic-era revenues. The company and its partner DualityBio plan to file a Biologics License Application (BLA) with the FDA in 2026 for the antibody-drug conjugate Trastuzumab Pamirtecan (BNT323/DB-1303), targeting advanced endometrial cancer.

New Phase 2 data presented at the Society of Gynecologic Oncology annual meeting showed a confirmed objective response rate of 47.9% among 145 heavily pre-treated patients. For a difficult-to-treat subgroup previously administered checkpoint inhibitors, the response rate held steady at 49.3%. The drug demonstrated efficacy across all HER2 expression levels, with the rate climbing to 73.1% for patients with the highest expression (IHC3+). The median progression-free survival was 8.1 months, with a median duration of response of 10.3 months.

The safety profile was deemed manageable. Treatment-related adverse events of grade 3 or higher occurred in 46.9% of participants, with grade 3 or higher pneumonitis or interstitial lung disease observed in 4.8%—a rate closely monitored for this drug class. A confirmatory Phase 3 trial, named Fern-EC-01, is already underway.

This regulatory milestone arrives as BioNTech navigates a profound business transformation. The company reported a net loss of €1.14 billion for the full year 2025 on revenue of just €2.9 billion, a stark contrast to the €17.3 billion peak during the Comirnaty boom. Management forecasts a further decline to between €2.0 billion and €2.3 billion for 2026.

Investor uncertainty surrounding this transition is reflected in the share price. The stock closed at €79.40 on Friday, marking a slight year-to-date decline of nearly 4%. It currently trades about 10% below its 200-day moving average and remains well below its 52-week high of nearly €106 reached in spring 2025.

Corporate governance is also in flux. The virtual annual general meeting on May 15, 2026, will not only address the 2025 financial statements but also vote on two new supervisory board members with expertise in oncology and clinical development. This move underscores the company's strategic focus as it concurrently searches for successors to its founding duo, who intend to step down by the end of the year.

The impending FDA submission provides a tangible near-term catalyst for a company whose future now hinges on successfully building a sustainable oncology business.